Send to

Choose Destination

See 1 citation found by title matching your search:

Circulation. 2018 Apr 6. pii: CIRCULATIONAHA.118.034309. doi: 10.1161/CIRCULATIONAHA.118.034309. [Epub ahead of print]

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: An Analysis from FOURIER.

Author information

TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Department of Molecular Medicine, University of Pavia and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
3rd Department of Medicine, Cardiology, and Intensive Care Medicine and Sigmund Freud University, Medical School, Vienna, Austria.
Lady Davis Carmel Medical Center, Haifa, Israel.
Hospital de Santa Cruz, Lisbon, Portugal.
Amgen, Thousand Oaks, CA.
Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Oslo University Hospital, Ulleval and Medical Faculty, University of Oslo, Oslo, Norway.


Background -The FOURIER trial recently showed that the PCSK9 inhibitor evolocumab significantly reduced major vascular events in patients with stable atherosclerotic cardiovascular disease, including patients with prior MI. Within the broad group of patients with prior MI, we hypothesized that readily ascertainable features would identify subsets that derive greater clinical risk reduction with evolocumab. Methods -The 22,351 patients with a prior MI were characterized based on time from most recent MI, number of prior MIs, and presence of residual multivessel coronary artery disease (≥40% stenosis in ≥2 large vessels). The relative and absolute risk reductions in major vascular events including the primary endpoint (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) and the key secondary endpoint (CV death, MI or stroke) with evolocumab in these subgroups were compared. Results -A total of 8402 patients (38%) were within 2 years of their most recent MI, 5285 patients (24%) had ≥2 prior MIs, and 5618 patients (25%) had residual multivessel CAD. In a multivariable adjusted model that simultaneously included all three high-risk features as well as other baseline covariates, more recent MI, multiple prior MIs, and residual multivessel coronary disease remained independent predictors of cardiovascular outcomes, with adjusted HRs for the primary endpoint of 1.37 (1.22-1.53), 1.78 (1.59-1.99) and 1.39 (1.24-1.56), all P<0.001. The relative risk reductions with evolocumab for the primary endpoint tended to be greater in the high-risk subgroups and were 20% (HR 0.80, 0.71-0.91), 18% (HR 0.82, 0.72-0.93), and 21% (HR 0.79, 0.69-0.91) for those with more recent MI, multiple prior MIs, and residual multivessel CAD, whereas they were 5% (HR 0.95, 0.85-1.05), 8% (HR 0.92, 0.84-1.02), and 7% (HR 0.93, 0.85-1.02) in those without, respectively. Given the higher baseline risk, the respective absolute risk reductions at 3 years exceeded 3% in the high-risk groups (3.4%, 3.7%, and 3.6%) vs. approximately 1% in the low-risk groups (0.8%, 1.3%, and 1.2%). Conclusions -Patients closer to their most recent MI, with multiple prior MIs or with residual multivessel CAD are at high risk for major vascular events and experience substantial risk reductions with LDL-C lowering with evolocumab. Clinical Trial Registration -URL: Unique identifier: NCT01764633.


Clinical trial; LDL-C; PCSK9; myocardial infarction

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center